title: The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.
authors.affiliation: Department of Microbiology, New York Medical College, Valhalla, New York 10595, USA.
authors.forename: Theodore S
authors.initials: TS
authors.lastname: Nowicki
authors.forename: Augustine L
authors.initials: AL
authors.lastname: Moscatello
authors.forename: Edward
authors.initials: E
authors.lastname: Shin
authors.forename: Stimson
authors.initials: S
authors.lastname: Schantz
authors.forename: Raj K
authors.initials: RK
authors.lastname: Tiwari
authors.forename: Jan
authors.initials: J
authors.lastname: Geliebter
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use; D002291:Carcinoma, Papillary / Q000378:metabolism* / Q000473:pathology* / Q000532:radiotherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D000077157:Sorafenib; D013964:Thyroid Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000532:radiotherapy; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007457:Iodine Radioisotopes; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D011505:Protein-Tyrosine Kinases; D014568:Urokinase-Type Plasminogen Activator